These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 32011653)
1. Co-located Opioid Use Disorder and Hepatitis C Virus Treatment Is Not Only Right, But It Is Also the Smart Thing To Do as It Improves Outcomes! Springer SA; Del Rio C Clin Infect Dis; 2020 Oct; 71(7):1723-1725. PubMed ID: 32011653 [No Abstract] [Full Text] [Related]
2. Hepatitis C Virus Reinfection Rate Among Persons Who Use Drugs and Are Maintained on Medication Treatment for Opioid Use Disorder. Springer SA Clin Infect Dis; 2020 Jun; 70(12):2703-2705. PubMed ID: 31346595 [No Abstract] [Full Text] [Related]
3. Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs. Rosenthal ES; Silk R; Mathur P; Gross C; Eyasu R; Nussdorf L; Hill K; Brokus C; D'Amore A; Sidique N; Bijole P; Jones M; Kier R; McCullough D; Sternberg D; Stafford K; Sun J; Masur H; Kottilil S; Kattakuzhy S Clin Infect Dis; 2020 Oct; 71(7):1715-1722. PubMed ID: 32009165 [TBL] [Abstract][Full Text] [Related]
4. Association between hepatitis C virus and opioid use while in buprenorphine treatment: preliminary findings. Murphy SM; Dweik D; McPherson S; Roll JM Am J Drug Alcohol Abuse; 2015 Jan; 41(1):88-92. PubMed ID: 25490610 [TBL] [Abstract][Full Text] [Related]
5. Hepatitis C and Stimulant Use Disorder: Challenges and Opportunities. Bach P; Ti L Clin Infect Dis; 2020 Dec; 71(11):3009. PubMed ID: 32161955 [No Abstract] [Full Text] [Related]
6. Spontaneous clearance of hepatitis C virus after long-term opiate dependence therapy with buprenorphine. Brunelle E; Ledru S; Rotily M; Becker C; Davion T; Vosgien V; Martinot M; Halfon P J Viral Hepat; 2004 Nov; 11(6):571-3. PubMed ID: 15500559 [No Abstract] [Full Text] [Related]
7. Hepatitis C virus infection and pain sensitivity in patients on methadone or buprenorphine maintenance therapy for opioid use disorders. Tsui JI; Lira MC; Cheng DM; Winter MR; Alford DP; Liebschutz JM; Mao J; Edwards RR; Samet JH Drug Alcohol Depend; 2015 Aug; 153():286-92. PubMed ID: 26048638 [TBL] [Abstract][Full Text] [Related]
8. Hepatitis C Virus Treatment Delivered via Telemedicine to Persons With Opioid Use Disorder. Talal AH; Dinani A; Brown LS JAMA Intern Med; 2022 Sep; 182(9):1011. PubMed ID: 35816336 [No Abstract] [Full Text] [Related]
9. Drug interactions between buprenorphine, methadone and hepatitis C therapeutics. Ogbuagu O; Friedland G; Bruce RD Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):721-31. PubMed ID: 27140427 [TBL] [Abstract][Full Text] [Related]
10. Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: realizing its potential. Sigmon SC; Bigelow GE Addiction; 2017 Mar; 112(3):386-387. PubMed ID: 27561982 [No Abstract] [Full Text] [Related]
11. Use of Buprenorphine to Treat Opioid Use Disorder. Bartholow LAM; Pope J J Psychosoc Nurs Ment Health Serv; 2018 Nov; 56(11):9-12. PubMed ID: 30383881 [TBL] [Abstract][Full Text] [Related]
12. Treatment of Opioid Dependence With Buprenorphine/Naloxone After Liver Transplantation: Report of Two Cases. Aldemir E; Coskunol H; Kilic M; Sert I Transplant Proc; 2016 Oct; 48(8):2769-2772. PubMed ID: 27788815 [TBL] [Abstract][Full Text] [Related]
13. Buprenorphine and Naloxone Versus Buprenorphine for Opioid Use Disorder in Pregnancy: A Cohort Study. Mullins N; Galvin SL; Ramage M; Gannon M; Lorenz K; Sager B; Coulson CC J Addict Med; 2020; 14(3):185-192. PubMed ID: 31567599 [TBL] [Abstract][Full Text] [Related]
14. Treating Opioid Use Disorder and Related Infectious Diseases in the Criminal Justice System. Winetsky D; Fox A; Nijhawan A; Rich JD Infect Dis Clin North Am; 2020 Sep; 34(3):585-603. PubMed ID: 32782103 [TBL] [Abstract][Full Text] [Related]
15. Characteristics and current clinical practices of opioid treatment programs in the United States. Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836 [TBL] [Abstract][Full Text] [Related]
16. A systematic review of sex differences in treatment outcomes among people with opioid use disorder receiving buprenorphine maintenance versus other treatment conditions. Ling S; Mangaoil R; Cleverley K; Sproule B; Puts M Drug Alcohol Depend; 2019 Apr; 197():168-182. PubMed ID: 30831429 [TBL] [Abstract][Full Text] [Related]
17. A Case Report: Rapid Micro-Induction of Buprenorphine/Naloxone to Administer Buprenorphine Extended-Release in an Adolescent With Severe Opioid Use Disorder. Azar P; Wong JSH; Jassemi S; Moore E; Vo DX; Nikoo M; Young S Am J Addict; 2020 Nov; 29(6):531-535. PubMed ID: 32346944 [TBL] [Abstract][Full Text] [Related]
18. Utilization of buprenorphine and methadone among opioid users who inject drugs. Tsui JI; Burt R; Thiede H; Glick SN Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591 [TBL] [Abstract][Full Text] [Related]
19. Hepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders. Carey KJ; Huang W; Linas BP; Tsui JI J Subst Abuse Treat; 2016 Jul; 66():54-9. PubMed ID: 26988423 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy Volunteers. Nasser AF; Heidbreder C; Liu Y; Fudala PJ Clin Pharmacokinet; 2015 Aug; 54(8):837-49. PubMed ID: 25603822 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]